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Abstract
Background: Patients with pelvic mass are the most referred patients to gynecologist. The aim of this study was
to evaluate the ability of three malignancy risk indices (RMI 1, RMI 2 and RMI 3) and CA-125 to discriminate a
benign from a malignant pelvic mass in our region (North of Iran).
Methods: This retrospective study was performed on 182 women with pelvic masses referred to Yahyanejad
Hospital from 2007 to 2009. Ultrasound scans were scored as one point for each of the following characteristics:
multilocular cyst, solid areas, intra-abdominal metastases, ascites, and bilateral lesions. For each patient a total
ultrasound score (U) was calculated. The difference of the three RMI was based on the allocation of the U and M
scores. The sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of level of
serum CA-125, the RMI 1, 2 and 3 were compared.
Results: Mean age of the patients was 39.9 ± 9.3 years. Most of them were premenopausal (161 women or 88.4%).
A significant linear trend for malignancy was found by increasing age, ultrasound score, and serum CA-125. The
best performance of CA125 was at a cut-off 88 U/ml, with a sensitivity of 88%, a specificity of 97%, a positive
predictive value of 84%, and a negative predictive value of 99%. RMI 1 and 3 at the optimal cut off point of 265
and RMI2 at the optimal cut off point of 355, had a sensitivity of 91%, specificity of 96%, a positive predictive value
of 78%, and a negative predictive value of 99%.
Conclusion: In our population we found that there is no statistically significant difference in the performance of
three malignancy risk indices (RMI 1, RMI 2, and RMI 3) and CA125 in differentiating between benign and
malignant pelvic masses.
Background
Patients with pelvic mass are the most referred patients
to gynecologist. [1]. Ovarian cancer is one of the pelvic
masses, the second most common gynecologic malig-
nancy, the fifth cause of death due to cancers, and has
more mortality than the other gynecologist malignancies
[2,3]. Most cases are diagnosed at high stage where prog-
nosis is very poor [4,5]. Regarding differentiation of
benign versus malignant pelvic masses before surgery
was difficult, therefore, Jacob et al. developed a Risk of
Malignancy Index (RMI) based on serum level of CA125,
menopausal state and ultra sound findings[6]. The RMI
has been adjusted by Tingulstad et al. [7] in 1996 (RMI2)
and again modified in 1999 (RMI3) [8]. The RMI is a sui-
table index for evaluation of pelvic mass before surgeries
and confirms previous studies indicating that RMI
improves the discrimination between non malignant and
malignant pelvic masses[5,9].
In many studies, cut off value of 200 for RMI1 is the
best discrimination for benign and malignant pelvic
masses because of its high sensitivity and specificity
levels[5]. The aim of this study was to evaluate the abil-
ity of three malignancy risk indices (RMI 1, RMI 2 and
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Methods
This retrospective study included the records of 182
consecutive women with pelvic masses, who were
admitted for laparotomy between 2007 and 2009, at
Yahyanejad Gynaecological Unit after signing a consent
form approved by the Research Ethics Committee of
Babol Medical University. Preoperative serum levels of
CA-125 were measured by ELISA (Germany Roche Kit
in the same laboratory), an ultrasonographic evaluation
of their pelvic mass using a 2-7 MHZ abdominal trans-
ducer (General Electric, America) and a 12 MHZ trans-
vaginal probe. Postmenopausal status was defined as
more than 1 year of amenorrhea or an age of more than
50 years in women who have had a hysterectomy. Then
RMI 1, 2, and3 were calculated for each patient. In all
patients underwent the laparotomy, the histological
specimens were sent to the pathology laboratory for the
histopathologic diagnosis.
Calculation of RMI
Ultrasound scans were scored as one point for each of
the following characteristics: multilocular cyst, solid
areas, intra-abdominal metastases, ascites, and bilateral
lesions. For each patient a total ultrasound score (U)
was calculated. The difference of the three RMI is based
on the allocation of the U and M scores.
R M I1=U×M×C A 1 2 5 ;a nu l t r a s o u n ds c o r eo f0
considered as U = 0, a score of 1 considered as U = 1,
and a score of ? 2 considered as U = 3. Premenopausal
status considered as M = 1 and postmenopausal status
considered as M = 3. The serum level of CA125 was
used directly in the calculation[6].
R M I2=U×M×C A 1 2 5 ;a nu l t r a s o u n ds c o r eo f0
or 1 considered as U = 1, and a score of ¿ 2 considered
as U = 4. Premenopausal status considered as M = 1
and postmenopausal status considered as M = 4. The
serum level of CA125 was used directly in the calcula-
tion[7].
RMI 3 = U × M × CA125; an ultrasound score of 0 or
1 considered as U = 1, and a score of ¿ 2 considered as
U = 3. Premenopausal status considered as M = 1 and
postmenopausal status considered as M = 3. The serum
CA125 level was used directly in the calculation[8].
Statistical analysis
All data was analysed by SPSS18. We used the T-Test,
Pearson Chi-square and Mann-Whitney U. Receiver
Operating Characteristics (ROC) Curve was plotted
and the sensitivity, specificity, positive(PPV) and nega-
tive predictive values(NPV) were determined. The
McNemar’s test was used when testing differences in
performances between RMI 1, RMI 2 and RMI 3.
A probability value of P < 0.05 was considered to be
statistically significant.
Results
Mean age of the patients was 39.9 ± 9.3 years. Most of
them were premenopausal (161 women or 88.4%). The
distribution of age, menopausal status, ultrasound
score (U) and serum CA-125 level in women with
benign and malignant pelvic mass were described in
Table 1. In univariate analysis, a significant linear
trend for malignancy was found by increasing age,
ultrasound score, and serum CA-125. Table 2 lists the
histology results, indicating that 158(87.3%), 23(12.7%)
and 1(0.5%) were benign, malignant and tuberculosis
masses, respectively.
The performance of RMI 1, RMI 2, RMI 3, and CA-
125 at different cutoff levels are presented in Table 3. A
direct comparison of the three RMI indices showed that
there were not any significant difference between RMI1
and 3 at a cutoff level of 265 and RMI2 at a cutoff level
of 355 (p > 0.05). The performance of RMI 1, RMI 2,
RMI 3 and CA125 are presented in receiver operator
characteristic curves (Figure 1). The detail of false posi-
tive and false negative cases based on the cut-off level
criteria of RMI 1, 2, 3 and CA125 according to their his-
tology are shown in Table 4.
Discussion
Our study showed the usefulness of the CA125 in prere-
ferral evaluation of patients with demonstrated pelvic
masses. We were determined that the different serum
level of CA 125 in benign and malignant pelvic mass is
similar to other studies [1,10]. The best performance of
CA125 in our study was at a cut-off 88 U/ml, with a
sensitivity of 88%, a specificity of 97%, a positive predic-
t i v ev a l u eo f8 4 % ,a n dan e g a t i v ep r e d i c t i v ev a l u eo f
Table 1 The distribution of age, menopausal status,
ultrasound score (U), serum CA 125 level in women with
benign and malignant pelvic masses
Parameter Benign
(n = 158)
malignant
(n = 23)
P-value
Age (mean) 38.7 ± 8.3 47.7 ± 12.5 0.003*
menopausal status (M)
Premenopausal 145(91.8%) 16(69.9%) 0.002*
Post menopausal 13(8.2%) 7(30.4%)
Ultrasound score (U)
U = 0 45(28.5%) 0 (0%) 0.001*
U = 1 50(31.6%) 0(0%)
U = 2-5 63(39.9%) 23(100%)
SerumCA-125(median)(U/ml) 21 112 < 0.001*
*P <0.05
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Page 2 of 499%. Although, this good performance might lie on the
distribution of tumor histology, which we showed in
table 2.
The results of previous studies describe that many stu-
dies showed the best cut off point for RMI is 200
[1,5-8,11]. However in this study, RMI 1 and 3 at the
optimal cut off point of 265 and RMI2 at the optimal
cut off point of 355, had a sensitivity of 91%, specificity
of 96%, a positive predictive value of 78%, and a nega-
tive predictive value of 99%. Bailey et al. study on 182
women with pelvic masses indicated an RMI > 200 had
a sensitivity of 88.5% for diagnosing invasive lesions[12]
while Engelen et al. study on 302 women with pelvic
mass indicated an RMI at a cut off point of 250 had a
sensitivity of 88.2%, a specificity of 74.3%, a PPV of
71.3%, a NPV of 90% for diagnosing invasive lesions[13].
A systematic review study by Geomini P et al. in 2009,
116 diagnostic studies for adnexal malignancy was
reviewed. The reported result showed that at the cut off
point of 200, RMI has a sensitivity of 78% and specificity
87% for malignant mass diagnoses[14] which is similar
to our report.
When RMIs cutoff was set at 265 or 355 and CA125
at 88 U/ml, all borderline tumors (mucinous adenocarci-
noma and serous adenocarcinoma) and all stage I, were
correctly identified prior to surgery, this increased the
sensivity but not at the expense of increasing the false
positive rate. Thus these cut offs are very useful at the
peripheral hospitals and health centers to accelerate
prompt referral of positive cases to tertiary hospitals.
We showed that CA-125 at the cut-off 88 U/ml per-
formed as well as the RMI 1 and 3 at a cut-off 265 and
RMI 3 at a cut-off 355 in differentiating between benign
and malignant pelvic masses.
Table 2 Definitive histopathological diagnosis of adnexal
masses
Diagnosis n %
Ovarian cancer
Stage I 8 4.3
Stage II 1 0.5
Stage III 11 6.0
Stage IV 3 1.6
Total malignant tumors 23 12.6
Metastatic tumor 2 1.1
Granulosa cells tumor 2 1.1
Serous papillary adenocarcinoma 9 4.9
dysgerminoma 1 0.5
Clear cell adenocarcinoma 1 0.5
Serous cystadenoma 1 0.5
Endometrioma 37 20.3
Dermoid cyst 29 15.9
hemorrhagic cyst 10 5.5
Paratubal cyst 21 11.5
Follicular simple cyst 10 5.5
Leiomyoma 10 5.5
Corpus luteum cyst 18 9.9
inclusion cyst 2 1.1
Borderline Tumors
Mucinous adenocarcinoma 6 3.2
Serous adenocarcinoma 2 1.1
Infective conditions
Tuberculosis mass 1 0.5
Table 3 Sensitivity, specificity, positive, negative
predictive values of three RMI and CA125
Methods Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
RMI 1&3 (cutoff: 200) 91 88 53 99
RMI 2 (cutoff: 200) 91 79 39 98
RMI 1&3 (cutoff: 265) 91 96 78 99
RMI 2 (cutoff: 355) 91 96 78 99
CA-125 (cut-off: 88 U/
mL)
87 97 84 99
Figure 1 ROC curve showing the relationship between
specificity and sensitivity for RMI 1, RMI 2, RMI 3 and CA125 in
differentiating between benign and malignant pelvic masses.
Table 4 False-positive cases and false-negative cases of
three malignancy risk indices RMI 1, 2, 3 and CA125
RMI 1
(cutoff:
265)
RMI 2
(cutoff:
355)
RMI 3
(cutoff:
265)
CA125
(cut off:
88)
False-positive cases
endometriosis 5 5 5 3
Mucinous
cystadenoma
1111
False-negative cases
granulosa cell
tumor
1111
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In our population we found that there is no statistically
significant difference in the performance of three malig-
nancy risk indices (RMI 1, RMI 2, and RMI 3) and
CA125 in differentiating between benign and malignant
pelvic masses.
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